Current and future preparative regimens for bone marrow transplantation in thalassemia

Rainer Storb*, Cong Yu, H. Joachim Deeg, George Georges, Hans Peter Kiem, Peter A. McSweeney, Richard A. Nash, Brenda M. Sandmaier, Keith M. Sullivan, John L. Wagner, Mark C. Walters

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


Preparative regimens for marrow allografts in thalassemia have two objectives. One is eradication of diseased marrow and the other suppression of host-versus-graft (HVG) reactions so that the allograft survives. A common regimen to accomplish these goals has combined high-dose busulfan with cyclophosphamide. Postgrafting immunosuppression with cyclosporine/methotrexate has been used for GVHD prevention. Some patients may die from regimen-related toxicity. Overall event-free survival is 75%. Occasional patients have become mixed donor/host hematopoietic chimeras and, yet, disease symptoms have abated. This has raised the possibility of developing safer and less toxic transplant programs that result in stable mixed hematopoietic chimerism. We have devised such a program in dogs consisting of a nonlethal dose of total body irradiation (200 cGy) before and a novel combination of mycophenolate mofetil and cyclosporine after transplant. Mixed donor/host chimerism (≤ 50% donor cells in all lineages) has persisted for > 80 weeks, even though immunosuppression was discontinued after five weeks.

Original languageEnglish (US)
Pages (from-to)276-287
Number of pages12
JournalAnnals of the New York Academy of Sciences
StatePublished - 1998

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology
  • General Neuroscience
  • History and Philosophy of Science


Dive into the research topics of 'Current and future preparative regimens for bone marrow transplantation in thalassemia'. Together they form a unique fingerprint.

Cite this